recurrence non-curable liver cancer
Conditions
Interventions
Case series:EpCAM CART
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients should meet the following criteria to participate in the experiment: 1. have signed informed consent; 2. aged 18 to 75 years male and female; 3. hepatocellular carcinoma recurrence after resection or liver transplantation,after resection of postoperative pathology immunohistochemistry confirmed tumor immunohistochemistry suggestive EpCAM (+); 4. Liver function child A level, before the group of conventional blood tips white blood cell count within the normal range, coagulation function is normal;no radical resection indications, only through interventional treatment of patients; 5. tumor characteristics can meet any of the following conditions: (1) pathologic diaglosis of hepatocellular carcinoma or cholangiocarcinoma after sugery,no radical resection indications after Multidisciplinary discussion, postoperative liver recurrence to meet BCLC B, (more than a single greater than 5cm, 2-3 more than 3cm standard), may or may not be associated with distant metastasis.pathologic diaglosis of Colorectal cancer liver metastasis or pancreatic carcinoma Liver metastasis, When the primary lesion had been eradicated, the oncologist decided that the prognosis of chemotherapy or targeted therapy was poor, and the liver tumor was not able to achieve radical resection (R0),which means: multiple tumors are more than 5 or single tumor greater than 10 cm, or the liver is evaluated by the physician after liver resection < 50%, or metastatic lesion is positive; may or may not be associated with distant metastasis. (2) patients are reluctant to continue surgery, radiofrequency treatment, chemoradiotherapy and so on.
Exclusion criteria
Exclusion criteria: Patients may be excluded from this study if they meet one of the following criteria: 1. with other malignancies; 2. patients are using antineoplastic agents and any other research drugs within 2 weeks of the same period; 3. patients with central nervous system Disease, mental illness, unstable angina, congestive heart failure, severe arrhythmia or other uncontrollable serious illness; 4. patient history of drug or similar structural allergy; 5. pregnancy, breastfeeding or urine pregnancy test Positive; 6. baseline examination of serious infection, bleeding, liver dysfunction or other postoperative complications and life-threatening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate; | — |
Countries
China
Contacts
Public ContactJiayin Yang
West China Hospital, Sichuan University
Outcome results
None listed